Knight Therapeutics (TSX:GUD) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:GUD Knight Therapeutics Inc TSX:GUD
73 GF Score
Price C$9.69
GF Value C$8.65
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Knight Therapeutics Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

TSX:GUD
73GF Score
Knight Therapeutics Inc TSX:GUD
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Knight Therapeutics (TSX:GUD) Overvalued in 2026?

Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued. The current stock price of C$9.69 is trading 12% above its estimated GF Value™ of C$8.65. GuruFocus considers Knight Therapeutics to be Modestly Overvalued.

Key valuation signals for TSX:GUD:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: C$8.65 vs. price of C$9.69 (12% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the TSX:GUD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Knight Therapeutics Business Description

Other Exchanges KHTRF:USA
Address 100 Alexis Nihon Boulevard, Suite 600, Saint-Laurent, QC, CAN, H4M 2P2
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
73GF Score

Get the complete analysis for TSX:GUD

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$9.69
Price
C$8.65
GF Value